This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Recurrent Non-small Cell Lung Cancer or Stage IV Non-small Cell Lung Cancer
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This phase I trial studies the side effects and best dose of PI3K inhibitor BKM120 when given together with carboplatin and pemetrexed disodium in treating patients with stage IV non-small cell lung cancer. PI3K inhibitor BKM120 and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving PI3K inhibitor BKM120, carboplatin, and pemetrexed disodium together may kill more tumor cells

Provided treatments

  • Drug: PI3K inhibitor BKM120
  • Drug: pemetrexed disodium
  • Drug: carboplatin
  • Other: laboratory biomarker analysis
  • Other: pharmacological study
  • Procedure: quality-of-life assessment

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01723800. The sponsor of the trial is City of Hope Medical Center and it is looking for 9 volunteers for the current phase.
Official trial title:
Phase I Trial of BKM120 in Combination With Carboplatin and Pemetrexed in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)